Completed PHASE2 INTERVENTIONAL 3-arm NCT00347919

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer

A Phase II, Open-Label, Randomized, Multicenter Trial of GW786034 (Pazopanib) in Combination With Lapatinib (GW572016) Compared to Lapatinib Alone as First Line Therapy in Subjects With Advanced or Metastatic Breast Cancer With ErbB2 Fluorescence In Situ Hybridization (FISH) Positive Tumors

Sponsor: GlaxoSmithKline

Conditions Neoplasms, Breast

Interventions lapatinib (GW572016) 1000 mg lapatinib (GW572016) 1500 mg pazopanib (GW786034) 400 mg pazopanib (GW786034) 800 mg

Updated 8 times since 2017 Last updated: Jan 28, 2016 Started: Jul 31, 2006 Primary completion: Aug 31, 2008 Completion: Mar 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Neoplasms, Breast and is currently completed. GlaxoSmithKline leads this study, which shows 8 recorded versions since 2006 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Dec 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Dec 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jul 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States , Alhambra, United States , Bakersfield, United States , Bandar Tun Razak, Cheras, Malaysia , Bangalore, India , Bangkok, Thailand , Besançon, France , Birmingham, United Kingdom , Budapest, Hungary , Callao, Peru and 65 more locations